Stock Screener App

無料 -

インストール

61.59

8.16% 4.71

Monopar Therapeutics Inc (MNPR)

概要ニュース株価時系列 Financials ディスカッション予測

Monopar Therapeutics Inc (MNPR) 最新ニュース

Monopar Therapeutics (NASDAQ:MNPR) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance

[ARS] Monopar Therapeutics SEC Filing - Stock Titan

[DEF 14A] Monopar Therapeutics Definitive Proxy Statement - Stock Titan

(MNPR) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily

MNPR (Monopar Therapeutics Inc.) slips 2.56% after Q4 2025 earnings miss on larger than expected per share loss.ROIC - Xã Thanh Hà

Analysts Offer Insights on Healthcare Companies: Monopar Therapeutics Inc (MNPR), ClearPoint Neuro (CLPT) and CG Oncology, Inc. (CGON) - The Globe and Mail

MNPR Stock Price, Quote & Chart | MONOPAR THERAPEUTICS INC (NASDAQ:MNPR) - ChartMill

Monopar Therapeutics stock maintained at Buy by Lake Street on trial data - Investing.com Canada

BTIG Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Maintains Target Price $104 - Moomoo

Monopar Therapeutics stock maintained at Buy by BTIG on trial data - Investing.com Canada

Monopar Reports Phase 3 Data Showing ALXN1840 Provides Greater Neurologic Benefit Versus Standard of Care in Wilson Disease Patients - Minichart

ALXN1840 Poised to Redefine Wilson Disease Treatment Standards: Phase 3 Success, De-Risked Profile, and Buy Rating Justification - TipRanks

Monopar Highlights Strong Phase 3 Data for ALXN1840 - TipRanks

Monopar (MNPR) unveils Phase 3 ALXN1840 neurologic gains and plans mid-2026 NDA - Stock Titan

Lake Street Initiates Coverage of Monopar Therapeutics (MNPR) with Buy Recommendation - MSN

MNPR (Monopar Therapeutics) posts wider Q4 2025 loss and zero revenue, shares dip 1.5 percent on weak results. - Newser

Monopar Therapeutics (MNPR) Shows Promising Results in Wilson Di - GuruFocus

Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026 - The Manila Times

Monopar Therapeutics Reports Positive Phase 3 Trial Results for ALXN1840 in Wilson Disease Patients at AAN Annual Meeting 2026 - Quiver Quantitative

Wilson disease study: 9% worsened on ALXN1840 vs 25% on standard care - Stock Titan

Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat

Monopar Therapeutics (MNPR) Stock Sector Perform (Weakens) 2026-04-16High Volume Stocks - Xã Vĩnh Công

How (MNPR) Movements Inform Risk Allocation Models - Stock Traders Daily

Chardan Capital Reaffirms Buy Rating on MNPR with $100 Price Tar - GuruFocus

Monopar Therapeutics (NASDAQ:MNPR) Lowered to Strong Sell Rating by Wall Street Zen - MarketBeat

Is Monopar Therapeutics Inc a momentum stock2026 Earnings Surprises & Weekly Top Gainers Trade List - baoquankhu1.vn

Is Monopar Therapeutics Inc stock technically oversold2026 Risk Factors & Real-Time Chart Breakout Alerts - baoquankhu1.vn

Q1 EPS Estimate for Monopar Therapeutics Boosted by Analyst - defenseworld.net

Monopar Therapeutics Inc (MNPR) Gets a Buy from JonesTrading - The Globe and Mail

Brookline Capital Markets Forecasts MNPR Q1 Earnings - MarketBeat

Gains Report: Will Monopar Therapeutics Inc benefit from sector rotationQuarterly Trade Review & Long Hold Capital Preservation Plans - baoquankhu1.vn

Trading Systems Reacting to (MNPR) Volatility - Stock Traders Daily

MNPR Stock News Today | Earnings, Events & Price Alerts - Intellectia AI

Monopar Therapeutics Inc. (1IY0.SG) stock price, news, quote and history - Yahoo Finance Singapore

Monopar Therapeutics Inc. (1IY0.SG) Stock Price, News, Quote & History - Yahoo! Finance Canada

[Form 4] Monopar Therapeutics Insider Trading Activity - Stock Titan

Monopar Therapeutics (MNPR) COO gains shares through RSU vesting and tax withholding - Stock Titan

Monopar Therapeutics Inc. 2025 Annual Report Amendment: Financial Highlights, Corrections, and Key SEC Filings - Minichart

Monopar Therapeutics | 10-K/A: Annual report (Amendment) - Moomoo

Monopar (NASDAQ: MNPR) 10-K/A shows $13.7M loss but strong cash - Stock Titan

HC Wainwright Brokers Reduce Earnings Estimates for MNPR - MarketBeat

Monopar Therapeutics Inc. (1IY0.SG) Analyst Ratings, Estimates & Forecasts - Yahoo! Finance Canada

Monopar Therapeutics Inc (MNPR) Receives a Buy from Lake Street - The Globe and Mail

Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail

MNPR SEC FilingsMonopar Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan

MNPR's Rating Maintains 'Buy' by Chardan Capital: March 30, 2026 - GuruFocus

Chardan Capital Reaffirms "Buy" Rating for Monopar Therapeutics (NASDAQ:MNPR) - MarketBeat

Monopar Therapeutics stock price target maintained at $104 by BTIG - Investing.com Canada

Monopar Therapeutics Inc. Q4 and Full Year 2025 Earnings: Net Loss Narrows to $13.7M - Bayelsa Watch

Monopar Therapeutics (STU:1IY0) NonCurrent Deferred Revenue : €0.00 Mil (As of Sep. 2025) - gurufocus.com

Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update - The Manila Times

Leerink reiterates Monopar stock rating on Wilson disease drug potential By Investing.com - Investing.com Canada

Raymond James reiterates Monopar stock rating on NDA timing shift By Investing.com - Investing.com Canada

Is Flanigans Enterprises Inc stock a hidden gem2026 Big Picture & Detailed Earnings Play Strategies - baoquankhu1.vn

Monopar Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com

MNPR: ALXN1840 advances toward NDA in 2026 as financials improve and cash reserves strengthen - TradingView

Monopar (NASDAQ: MNPR) details 2025 loss and ALXN1840 NDA plan - Stock Titan

ROIV

$28.50

0.78%

RPRX

$50.76

2.57%

BNTX

$92.69

3.01%

INSM

$138.73

1.11%

RVMD

$147.88

0.02%

ONC

$305.60

2.86%

Yahooで開く | Google で開く | Finviz で開く | マーケットウォッチで開く | エドガーでオープン | ロイターで開く